Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Howe, Yamini J.; Thom, Robyn P.; Notson, Erin E.; McDougle, Christopher J.; Palumbo, Michelle L.
• Is Part Of: Journal of developmental and behavioral pediatrics. Volume 43:Issue 1(2022)
• Publication Date: 2022-01
• Subjects: Down syndrome -- Generalized Anxiety Disorder -- Buspirone -- psychopharmacology -- adults; Child development -- Periodicals; Developmental disabilities -- Periodicals; Behavior disorders in children -- Periodicals; Learning disabilities -- Periodicals; Child psychiatry -- Periodicals; 618.92805
• DOI: 10.1097/DBP.0000000000000970
• Languages: English
• ISSNs: 0196-206X

Abstract

ABSTRACT: Objective: Reports on the pharmacologic treatment of anxiety, including generalized anxiety disorder (GAD), in individuals with Down syndrome (DS) are lacking. Methods: We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone. Results: Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases. Conclusion: Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities.